论文部分内容阅读
目的:探讨疏血通注射液联合巴曲酶治疗急性进展性脑梗死的临床疗效及对血清hs-CRP、IL-6水平的影响。方法:选择82例急性进展性脑梗死患者为研究对象,根据随机数字表法分为观察组与对照组,每组41例,对照组予巴曲酶治疗,观察组联合应用疏血通注射液,比较两组患者治疗前后NIHSS评分、BI评分及血清hs-CRP、IL-6水平的变化。结果:观察组与对照组患者治疗后NIHSS评分分别为(9.81±1.94)、(13.33±2.38)分,均较治疗前的(18.78±3.51)、(17.64±4.86)分明显降低,BI评分为(62.46±11.16)、(53.25±10.72)分,较治疗前的(31.58±12.87)、(32.64±10.96)分明显提高,且观察组优于对照组,差异有统计学意义(P<0.05);治疗后,观察组治疗有效率为80.49%,明显高于对照组的63.41%,差异有统计学意义(P<0.05);观察组与对照组患者治疗后,血清hs-CRP、IL-6水平分别为(12.26±2.21)mg/L、(19.62±6.48)ng/L和(15.43±3.18)mg/L、(24.17±6.06)ng/L,均较治疗前的(19.62±3.44)mg/L、(42.56±10.47)ng/L和(20.26±4.08)mg/L、(41.92±11.58)ng/L明显降低,且观察组明显低于对照组,差异有统计学意义(P<0.05)。结论:疏血通注射液联合巴曲酶治疗急性进展性脑梗死具有较好的临床疗效,可显著降低患者血清hs-CRP、IL-6水平并改善神经功能缺损程度,改善日常生活活动能力。
Objective: To investigate the clinical efficacy of Shuxuetong injection combined with batroxobin in the treatment of acute progressive cerebral infarction and its effect on serum hs-CRP and IL-6 levels. Methods: A total of 82 patients with acute progressive cerebral infarction were selected as study subjects. According to the random number table, the patients were divided into observation group and control group, 41 cases in each group. The control group was treated with batroxobin. The observation group was treated with Shuxuetong injection The changes of NIHSS score, BI score, serum hs-CRP and IL-6 levels before and after treatment were compared between the two groups. Results: The NIHSS scores of the observation group and the control group were (9.81 ± 1.94) and (13.33 ± 2.38) after treatment, respectively, which were significantly lower than those before treatment (18.78 ± 3.51) and (17.64 ± 4.86), respectively (62.46 ± 11.16) and (53.25 ± 10.72) points respectively, which were significantly higher than those before treatment (31.58 ± 12.87) and (32.64 ± 10.96) points, and the observation group was superior to the control group (P <0.05) After treatment, the effective rate of observation group was 80.49%, significantly higher than that of control group (63.41%), the difference was statistically significant (P <0.05); After treatment, the serum hs-CRP, IL- (19.62 ± 6.48) ng / L and (15.43 ± 3.18) mg / L and (24.17 ± 6.06) ng / L, respectively, compared with those before treatment (19.62 ± 3.44) mg L, (42.56 ± 10.47) ng / L and (20.26 ± 4.08) mg / L, (41.92 ± 11.58) ng / L and the observation group was significantly lower than the control group ). Conclusion: Shuxuetong injection combined with batroxobin in the treatment of acute progressive cerebral infarction has a good clinical efficacy, can significantly reduce the serum hs-CRP, IL-6 levels and improve the degree of neurological deficits and improve the activities of daily living.